Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
Open accessThe DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 1×
“The hypothesis first proposed by Thomas and Burnet in the 1970s implied that the immune response to tumor occurred at an early stage in tumor development—‘‘eradicating the cancer before it became apparent’’ [13, 14].”
BackgroundTolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820 · cited 1×
“Similar observations were also reported by our group where immunization with irradiated RENCA cells (murine renal carcinoma) infected with DISC-HSV (disabled infectious single cycle–herpes simplex virus) that enhanced immunity to tumor challenge with live parental tumor cells that induced cell death by necrosis as opp…”
ResultInhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563 · cited 1×
“The caspase-8 inhibitor, cellular FLICE-inhibitory protein (cFLIP), is expressed in many tumors making them resistant to death receptor–mediated apoptosis [30].”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 2×
“mouse tumor cells prevents their rejection in preimmunized mice, correlating with the lack of specific T-cell accumulation at the tumor site [43].”
BackgroundThe TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887 · cited 1×
“Members of the TNFR superfamily including CD27, CD30, 4-1BB and OX40 have also been shown to transmit a costimulation signals to leukocytes [112, 113].”
BackgroundA cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857 · cited 2×
“The mechanisms of tumor escape from immune recognition/destruction are likely to be multifactorial, including down-regulation of MHC class I molecules [23–26], loss of tumor antigens [27, 28], defective death receptor signaling [29–33], lack of costimulation [34], and production of immunosuppressive cytokines [35] and…”
BackgroundCD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337 · cited 1×
“AccumulationofGr1CD11bcells and their ability to inhibit the T-cell function has been reported in cancer patients [130].”
BackgroundSuppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific
Thornton, A. M., & Shevach, E. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.183 · Cited by 1,229 · cited 1×
“CD4CD25 T cells are known to be immunoregulatory and are important in immunological tolerance to self-antigens [39] and inhibition of T-cell proliferation [124].”
BackgroundFrumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133 · cited 1×
“Indoleamine 2,3-dioxygenase (IDO) is an enzyme ubiquitously distributed in mammalian tissues and cells converting tryptophan to N-formylkynurenine [41].”
BackgroundWoo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060 · cited 1×
“The expression of Fas ligand (FasL), a well-known cell death receptor ligand, on tumor cells has been implicated in their evasion of immune surveillance [29, 32, 33, 80, 81].”
BackgroundNatural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058 · cited 3×
“The eventual fate of the tumor is therefore determined by the net effect of immune activation and inhibition [ 15 ].”
BackgroundInfluentialPotential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028 · cited 1×
“In humans, only a discrete subset of APCs that coexpress the cell surface markers CD123 and CCR6 was shown to express IDO and inhibit T-cell proliferation in vitro [47].”
BackgroundSutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · cited 1×
“Sutmuller and colleagues [ 40 ] demonstrated that the depletion of CD4 + CD25 + T cells”
BackgroundCaspase activation: The induced-proximity model
Salvesen, G. S., & Dixit, V. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.10964 · Cited by 933 · cited 1×
“The Fas/FasL complex forms and engages caspase-8 which autoactivates itself and cleaves caspase-3, caspase-6, and caspase-7 [84].”
BackgroundMonoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898 · cited 1×
“response, leading to the eradication of established AG104A sarcomas and P815 mastocytomas in vivo [118].”
BackgroundA Phagosome-to-Cytosol Pathway for Exogenous Antigens Presented on MHC Class I Molecules
Kovacsovics-Bankowski, M., & Rock, K. L. (1995) · Science · doi:10.1126/science.7809629 · Cited by 884 · cited 1×
“... carcinoma) infected with DISC-HSV (disabled infectious single cycle–herpes simplex virus) that enhanced immunity to tumor challenge with live parental tumor cells that induced cell death by necrosis as opposed to apoptosis [20] providing the immune system with additional activation as the cells were undergoing nec…”
BackgroundIkeda, H., Lethé, B., Lehmann, F., Van Baren, N., Baurain, J.-F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80426-4 · Cited by 762 · cited 1×
“Compound phenotype 2 or more independent mechanisms [50, 60, 61] 846”
BackgroundMyeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690 · cited 2×
“inhibiting antibody production, CTL generation, T-cell function, and lymphocytic proliferation [38, 129].”
BackgroundTryptophan catabolism and T-cell tolerance: immunosuppression by starvation?
Mellor, A. L., & Munn, D. H. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01520-0 · Cited by 648 · cited 1×
“This cytosolic enzyme catalyzes the initial and rate-limiting step in the catabolism of tryptophan in the kynurenine pathway [42].”
BackgroundEffect of interleukin‐10 on dendritic cell maturation and function
de Smedt, T., van Mechelen, M., De Becker, G., Urbain, J., Leo, O., & Moser, M. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270526 · Cited by 565 · cited 1×
“IL-10 has the ability to exert its effects in many ways: it inhibits antigen presentation, IL-12 production, and the induction of Th1 responses in vivo [99, 100].”
BackgroundMechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538 · cited 1×
“The Gr1 cells are also able to decrease CD3f molecule expression significantly [131], and inhibit MHC class I–dependent antigen-specific CD8 T cells [37].”
BackgroundRestifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527 · cited 1×
“In addition, immune suppression in tumor-bearing mice has been attributed to the presence of cells with an immature myeloid phenotype that express the granulocyte-monocyte markers Gr1CD11b [36], and accumulate in the spleens and lymph nodes [129] and blood of tumor-bearing mice (Ahmad et al.”
BackgroundSasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 484
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465 · cited 1×
“Suppression of allogeneic T-cell responses in vitro and in vivo by interstitial APCs was also shown to be IDO-dependent, and blockade of IDO activity with 1-MT (1-methyl-DL-tryptophan [45]) or addition of exogenous tryptophan allowed the recovery of T-cell proliferation in MLR assays [46].”
BackgroundTumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellström, I., & Hellström, K. E. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.523 · Cited by 462 · cited 1×
“[115] showed that the insertion of genes encoding B7.”
Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas
Gruss, H., & Dower, S. (1995) · Blood · doi:10.1182/blood.v85.12.3378.bloodjournal85123378 · Cited by 450 · cited 1×
“Members of the TNFR superfamily including CD27, CD30, 4-1BB and OX40 have also been shown to transmit a costimulation signals to leukocytes [112, 113].”
BackgroundMelcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., & Vile, R. G. (1998) · Nature Medicine · doi:10.1038/nm0598-581 · Cited by 445 · cited 1×
“Killing of tumor cells in situ by suicide gene transfer to induce cell death through a nonapoptotic pathway was shown to be associated with enhanced immunogenicity [19].”
BackgroundPardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Weinberg, A. D., Rivera, M.-M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2160 · Cited by 387 · cited 1×
“Costimulation through OX40L, for example, would be advantageous, since its expression is primarily detected on recently stimulated antigen-specific CD4 T cells [120], which is considered advantageous for generating CD8”
BackgroundHLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
Hicklin, D. J., Marincola, F. M., & Ferrone, S. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01451-3 · Cited by 376 · cited 1×
“Immune selection of tumorresistant CTLs and/or NK cells may explain the rapid progression and poor prognosis of cancers exhibiting HLA class I antigen down-regulation [49].”
BackgroundVEGF as a Mediator of Tumor-Associated Immunodeficiency
Ohm, J. E., & Carbone, D. P. (2001) · Immunologic Research · doi:10.1385/ir:23:2-3:263 · Cited by 371 · cited 2×
“cells by acting in the early stages of immunopoiesis [91].”
BackgroundKono, K., Salazar‐Onfray, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K., Nakazawa, T., Anderson, P., & Kiessling, R. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260620 · Cited by 359 · cited 4×
“FLICE/caspase-8–inhibitory protein (cFLIP) is a recently identified intracellular inhibitor of caspase-8 activation that potently inhibits death signaling mediated by all known death receptors, including Fas, TNFreceptor (TNF-R), and TNF-related apoptosis-inducing ligand receptors (TRAIL-Rs), The increased expression…”
BackgroundInfluentialKusmartsev, S. A., Li, Y., & Chen, S.-H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.779 · Cited by 355 · cited 1×
“inhibiting antibody production, CTL generation, T-cell function, and lymphocytic proliferation [38, 129].”
BackgroundGorsch, S. M., Memoli, V. A., Stukel, T. A., Gold, L. I., & Arrick, B. A. (1992) · PubMed · Cited by 343
Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J., Vivier, É., Anderson, P., & Kiessling, R. W. (1993) · PubMed · Cited by 339
Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., & Saito, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13119 · Cited by 338 · cited 1×
“molecule expression significantly [ 131 ], and inhibit MHC class I–dependent antigen-specific CD8 + T cells [37].”
BackgroundTolerance, Danger and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.immunol.12.1.991 · Cited by 335
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein
Medema, J. P., de Jong, J., van Hall, T., Melief, C. J. M., & Offringa, R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.7.1033 · Cited by 330 · cited 1×
“FLICE/caspase-8–inhibitory protein (cFLIP) is a recently identified intracellular inhibitor of caspase-8 activation that potently inhibits death signaling mediated by all known death receptors, including Fas, TNFreceptor (TNF-R), and TNF-related apoptosis-inducing ligand receptors (TRAIL-Rs), The increased expression…”
BackgroundMHC antigens and tumor escape from immune surveillance
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305 · cited 5×
“HLA-A, HLA-B, HLA-C locus down-regulation Alteration of transcriptional factors [50, 58, 59]”
BackgroundInfluentialMaeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., & Lotze, M. T. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118958 · Cited by 289 · cited 1×
“Restoring the ‘‘antigen loss’’ in the variant tumor cell line by simultaneously providing both the MART-1/Melan-A gene (by retroviral transfer) and the TAP-1 gene (by a bioballistic approach) resulted in tumor cell sensitivity to MART-1/ Melan-A–specific cytotoxic T lymphocytes, suggesting antigen loss and down-regula…”
BackgroundImmunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., Arancia, G., Anichini, A., Fais, S., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18809.x · Cited by 289
Tsushima, H., Kawata, S., Tamura, S., Ito, N., Shirai, Y., Kiso, S., Imai, Y., Shimomukai, H., Nomura, Y., Matsuda, Y., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8566583 · Cited by 284 · cited 1×
“High concentrations of TGF-b are also found in cancer patients [101] and are usually associated with ‘‘tumor progression’’ [102] and poor responses to immunotherapy [103].”
BackgroundSystemic and local immunosuppression in pancreatic cancer patients.
von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Jöhnk, C., Henne‐Bruns, D., Kremer, B., & Kalthoff, H. (2001) · PubMed · Cited by 279
Koopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.961 · Cited by 279 · cited 1×
“This phenomenon has been studied in a series of tumor samples by immunohistochemical techniques and has been shown to be widespread [48].”
BackgroundMaeda, H., & Shiraishi, A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.73 · Cited by 272
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259 · cited 1×
“However, resistance to this treatment modality by a number of poorly immunogenic tumors, including the TC-1 lung carcinoma and B16-F10 melanoma, was shown to be due to tumor antigen–specific CTLs’ ‘‘ignorance’’ rather than anergy or deletion; breaking CTL ignorance by peptide immunization was necessary for the anti-4-…”
BackgroundClark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G., Macintyre, A. R., Rojas, J., Bourdon, A., Bonner, P. L. R., Wang, L., et al. (2001) · Blood · doi:10.1182/blood.v98.10.2887 · Cited by 253 · cited 1×
“CML patients, for example, possess CTLs detectable by tetramer staining and cytotoxicity that recognize HLA-A3–restricted peptide, although the number of CTLs may be too few to mediate complete rejection of the cancer [12].”
BackgroundSelf-citationT Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function
Sharma, S., Stolina, M., Lin, Y., Gardner, B., Miller, P. W., Kronenberg, M., & Dubinett, S. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.5020 · Cited by 250 · cited 1×
“IL-10 has the ability to exert its effects in many ways: it inhibits antigen presentation, IL-12 production, and the induction of Th1 responses in vivo [99, 100].”
BackgroundSerrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239 · cited 1×
“HLA class I total loss b2m mutations [50–52] Alterations in antigen-processing machinery [50, 53]”
BackgroundBellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A., Emanuelli, G., & Rodeck, U. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65149-8 · Cited by 227
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214184 · Cited by 222
How melanoma cells evade trail-induced apoptosis
Hersey, P., & Zhang, X. D. (2001) · Nature Reviews Cancer · doi:10.1038/35101078 · Cited by 212
Natural mechanisms protecting against cancer
Jakóbisiak, M., Lasek, W., & Gołąb, J. (2003) · Immunology Letters · doi:10.1016/j.imlet.2003.08.005 · Cited by 206 · cited 1×
“The immune defense mechanisms are the least effective and final barrier in the natural mechanisms against cancer formation (carcinogenesis) [1].”
BackgroundSpontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions
Davidson, W. F., Giese, T., & Fredrickson, T. N. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1825 · Cited by 189 · cited 1×
“The expression of Fas ligand (FasL), a well-known cell death receptor ligand, on tumor cells has been implicated in their evasion of immune surveillance [29, 32, 33, 80, 81].”
Backgroundde Vries, T. J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D. J., & van Muijen, G. N. P. (1997) · PubMed · Cited by 187
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Yamaguchi, N., Yagita∥, H., & Okumura, K. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1896 · Cited by 183
Hunt, S. (2002) · Trends in Immunology · Cited by 172
Keating, P., Cromme, F., Duggan-Keen, M., Snijders, P., Walboomers, J., Hunter, R., Dyer, P., & Stern, P. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.346 · Cited by 169
Cabrera, C. M., Jiménez, P., Cabrera, T., Esparza, C., Ruiz‐Cabello, F., & Garrido, F. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00020.x · Cited by 164
Increased interleukin-10 serum levels in patients with solid tumours
Fortis, C., Foppoli, M., Gianotti, L. V., Galli, L., Citterio, G., Consogno, G., Gentilini, O., & Braga, M. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04213-9 · Cited by 164 · cited 1×
“IL-10 is a cytokine often quoted as being suppressive, and high levels of IL-10 have been reported in patients with melanoma [ 96 ] and pancreatic cancer [97, 98].”
BackgroundBuggins, A. G. S., Milojković, D., Arno, M. J., Lea, N. C., Mufti, G. J., Thomas, N. S. B., & Hirst, W. J. R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.6021 · Cited by 155 · cited 2×
“The T-cell immunosuppression induced by AML cells provides a mechanism by which leukemic clones could evade T cell–mediated lysis by inhibiting the NF-jB, c-myc, and pRb pathways [ 95 ].”
BackgroundCD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
Javia, L. R., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200301000-00009 · Cited by 147
Krasagakis, K., Thölke, D., Farthmann, B., Eberle, J., Mansmann, U., & Orfanos, C. E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.245 · Cited by 138 · cited 1×
“The levels of TGF-b are higher in patients with disseminated melanoma when compared to those with localized disease [104].”
BackgroundCDllc + Cells Modulate Pulmonary Immune Responses by Production of Indoleamine 2,3-Dioxygenase
Swanson, K. A., Zheng, Y., Heidler, K. M., Mizobuchi, T., & Wilkes, D. S. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0268oc · Cited by 129 · cited 1×
“enzyme was recognized for its antimicrobial activity by allowing cells to deplete tryptophan from intracellular pool or local microenvironment [ 44 ]; however, recently, IDO was reported to be constitutively expressed by most human tumors, and its expression by immunogenic mouse tumor cells prevents their rejection in…”
BackgroundAnalysis of HLA expression in human tumor tissues
Cabrera, T., López‐Nevot, M. Á., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0332-0 · Cited by 119 · cited 2×
“Progressive tumor growth occurs, in part, because the cancer cell is capable of escaping immune recognition and not because the immune system is defective [11].”
BackgroundHofbauer, G. F. L., Kamarashev, J. A., Geertsen, R., Böni, R., & Dummer, R. (1998) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1998.tb01720.x · Cited by 114
Inoshima, N., Nakanishi, Y., Minami, T., Izumi, M., Takayama, K., Yoshino, I., & Hara, N. (2002) · PubMed · Cited by 114
Clinical significance of the determination of angiogenic factors
Toi, M., Taniguchi, T., Yamamoto, Y., Kurisaki, T., Suzuki, H., & Tominaga, T. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00397-8 · Cited by 107 · cited 1×
“Vascular endothelial growth factor (VEGF) is secreted by many tumors [90], and in the past few years VEGF has been required as a contributory factor in tumor escape.”
BackgroundAntigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes
Bai, X.-F., Liu, J., Li, O., Zheng, P., & Liu, Y. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17656 · Cited by 105 · cited 1×
“The recurrence of tumors in mice that have responded favorably to transgenic T-cell adoptive therapy was found to correlate with the presence of tumor variants with mutations within the PIA epitope [77].”
BackgroundLissoni, P., Malugani, F., Bonfanti, A., Bucovec, R., Secondino, S., Brivio, F., Bravo, A. F., Ferrante, R., Vigoré, L., Rovelli, F., et al. (2001) · PubMed · Cited by 102
Osaki, M., Kase, S., Adachi, K., Takeda, A., Hashimoto, K., & Ito, H. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0505-z · Cited by 99 · cited 1×
“PI3 K inhibitors, such as LY294002, inhibit cell proliferation and increase apoptosis in the human gastric carcinoma cell line by the down-regulation of Mcl-2 and phosphorylated Bad proteins, which are antiapoptotic factors and belong to the Bcl-2 family [ 82 ].”
BackgroundPardoll, D. M. (2001) · Nature · doi:10.1038/35082676 · Cited by 98
Tuning tumor-specific T-cell activation: a matter of costimulation?
Abken, H., Hombach, A. A., Heuser, C., Kronfeld, K., & Seliger, B. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02180-4 · Cited by 88 · cited 1×
“Tumor cells are able to induce antigen-specific tolerance or anergy on the basis of MHC-1–restricted antigen presentation without the expression of costimulatory ligand(s) [ 114 ].”
BackgroundAltered MHC class I antigens in tumors
Algarra, I., Collado, A., & Garrido, F. (1997) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02912442 · Cited by 87
Hofbauer, G. F. L., Kamarashev, J. A., Geertsen, R., B�ni, R., & Dummer, R. (1998) · Melanoma Research · doi:10.1097/00008390-199808000-00007 · Cited by 81 · cited 2×
“The mechanisms of tumor escape from immune recognition/destruction are likely to be multifactorial, including down-regulation of MHC class I molecules [23–26], loss of tumor antigens [27, 28 ], defective death receptor signaling [29–33], lack of costimulation [34], and production of immunosuppressive cytokines [35] an…”
BackgroundCD4+ T-cell–epitope escape mutant virus selected in vivo
Ciurea, A., Hunziker, L., Martinic, M. M. A., Oxenius, A., Hengartner, H., & Zinkernagel, R. M. (2001) · Nature Medicine · doi:10.1038/89915 · Cited by 81 · cited 1×
“Transgenic mice expressing TCR for a single antigenic epitope have been used extensively in establishing antigenic mutation(s) as a mechanism for viral escape of T-cell recognition [75, 76].”
BackgroundSong, E., Chen, J., Ouyang, N., Su, F., Wang, M., & Heemann, U. W. (2001) · British Journal of Cancer · doi:10.1038/sj.bjc.6692042 · Cited by 77
Zheng, P., Sarma, S., Guo, Y., & Liu, Y. (1999) · PubMed · Cited by 73
Do CD4+CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?
Antony, P. A., & Restifo, N. P. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00002 · Cited by 72 · cited 1×
“However, it is thought that the mere depletion or blocking of T-regulatory cells is not sufficient to successfully treat established tumors [125].”
BackgroundFas Ligand on Tumor Cells Mediates Inactivation of Neutrophils
Chen, Y.-L., Chen, S., Wang, J., & Yang, B.-C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1183 · Cited by 70 · cited 1×
“The expression of Fas ligand (FasL), a well-known cell death receptor ligand, on tumor cells has been implicated in their evasion of immune surveillance [29, 32, 33, 80, 81].”
BackgroundThe new vaccines: building viruses that elicit antitumor immunity
Restifo, N. P. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80082-3 · Cited by 68
MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment
Mukherjee, P., Ginardi, A. R., Madsen, C. S., Tinder, T. L., Jacobs, F., Parker, J., Agrawal, B., Longenecker, B. M., & Gendler, S. J. (2001) · Glycoconjugate Journal · doi:10.1023/a:1022260711583 · Cited by 64 · cited 1×
“IL-10 is a cytokine often quoted as being suppressive, and high levels of IL-10 have been reported in patients with melanoma [96] and pancreatic cancer [97, 98].”
BackgroundMolecular strategies to define HLA haplotype loss in microdissected tumor cells
Ramal, L. M., Maleno, I., Cabrera, T., Collado, A., Ferrón, A., López‐Nevot, M. Á., & Garrido, F. (2000) · Human Immunology · doi:10.1016/s0198-8859(00)00171-3 · Cited by 60
Rohrlich, P. (2003) · International Immunology · doi:10.1093/intimm/dxg073 · Cited by 60
Alterations in T cells of cancer-bearers: whence specificity?
Levey, D. L., & Srivastava, P. K. (1996) · Immunology Today · doi:10.1016/0167-5699(96)10013-x · Cited by 60 · cited 1×
“Inhibition of a number of T lymphocyte functions in tumor-bearing hosts has been extensively investigated [121, 122], and suppressor cells have been shown to play a role in the progression of cancer [123].”
BackgroundUgurel, S., Uhlig, D., Pf�hler, C., Tilgen, W., Schadendorf, D., & Reinhold, U. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0489-1 · Cited by 52 · cited 1×
“This phenomenon was observed in PBMs of melanoma patients [ 70 ].”
BackgroundLozupone, F., Rivoltini, L., Luciani, F., Venditti, M., Lugini, L., Cova, A., Squarcina, P., Parmiani, G., Belardelli, F., & Fais, S. (2003) · European Journal of Immunology · doi:10.1002/immu.200310032 · Cited by 51 · cited 2×
“when injected showed enhanced tumor growth in mice depleted of neutrophils, suggesting that inactivation of neutrophils was an important mechanism by which tumors could escape destruction [ 78 ].”
BackgroundMethodA new β2 microglobulin mutation found in a melanoma tumor cell line
Pérez, B. F., Benitez, R., Fernández, M. A., Oliva, M. R., Soto, J. L., Serrano, S., López‐Nevot, M. Á., & Garrido, F. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.530607.x · Cited by 49
Real, L. M., Jiménez, P., Kirkin, A. F., Serrano, A., Garcia-Lora, A. M., Cantón, J., Zeuthen, J., Garrido, F., & Ruiz‐Cabello, F. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620000154 · Cited by 48 · cited 1×
“Compound phenotype 2 or more independent mechanisms [50, 60, 61] 846”
BackgroundLi, R., R�ttinger, D., Si, L.-S., Si, L.-S., & Wang, Y. (2003) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-003-0416-0 · Cited by 42 · cited 1×
“In non–small cell lung cancer (NSCLC) patients, the mRNA expression of IL-4, IL-10, TGF-a, and TGF-b1 was significantly higher than that of IL-2, IL-12, IL-18, and INF-c as determined in pleural effusion and tumor tissue [89].”
BackgroundCriteria to define HLA haplotype loss in human solid tumors
Ramal, L. M., Feenstra, M., Zwan, A. ‐. V. D., Collado, A., López‐Nevot, M. Á., Tilanus, M. G. J., & Garrido, F. (2000) · Tissue Antigens · doi:10.1034/j.1399-0039.2000.550507.x · Cited by 40
Ali, S., McLean, C. S., Boursnell, M. E. G., Martin, G., Holmes, C., Reeder, S., Entwisle, C., Blakeley, D. M., Shields, J. G., Todryk, S. M., et al. (2000) · PubMed · Cited by 39
Self-citationHLA class I expression in bladder carcinomas
Cabrera, T., Pedrajas, G., Cozar, J. M., Garrido, A., Vicente, J., Tallada, M., & Garrido, F. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00104.x · Cited by 36 · cited 1×
“down-regulation/loss [62]; expression was correlated to”
Wen, X., Mandelbaum, S., Li, Z. H., Hitt, M., Graham, F. L., Hawley, T. S., Hawley, R. G., & Stewart, A. K. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700321 · Cited by 36
Ali, S., Lynam, J., McLean, C. S., Entwisle, C., Loudon, P. T., Rojas, J. M., McArdle, S., Geng, L., Mian, S., & Rees, R. C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3512 · Cited by 35
Self-citationBcl-2 as a Target for Overcoming Chemoresistance in Small-Cell Lung Cancer
Fennell, D. A. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.012 · Cited by 33 · cited 2×
“PI3 K inhibitors, such as LY294002, inhibit cell proliferation and increase apoptosis in the human gastric carcinoma cell line by the down-regulation of Mcl-2 and phosphorylated Bad proteins, which are antiapoptotic factors and belong to the Bcl-2 family [82].”
BackgroundFusagene vectors: a novel strategy for the expression of multiple genes from a single cistron
Gäken, J. A., Jiang, J., Daniel, K., van Berkel, E., Hughes, C., Kuiper, M., Darling, D., Tavassoli, M., Galea‐Lauri, J., Ford, K. G., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301341 · Cited by 33 · cited 1×
“Recently, fusagene vectors were developed to encode multiple gene products as fusion proteins from a single cistron to increase the immunogenenicity of target tumor cells [116].”
BackgroundDown-regulation of the CD3-ζ chain in sentinel node biopsies from breast cancer patients
Schüle, J. M., Bergkvist, L., Håkansson, L., Gustafsson, B., & Håkansson, A. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1016009913699 · Cited by 32
Maiorana, A., Cesinaro, A. M., Fano, R. A., & Collina, G. (1995) · Clinical & Experimental Metastasis · doi:10.1007/bf00144017 · Cited by 30
Loss of Human Leukocyte Antigen Expression on Colorectal Tumor Cell Lines
Browning, M. J., Krausa, P., Rowan, A., Hill, A. B., Bicknell, D. C., Bodmer, J. G., & Bodmer, W. F. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199310000-00001 · Cited by 29 · cited 1×
“HLA allelic loss Mutations of HLA class I genes [50, 57] IV.”
BackgroundHigh frequency of HLA-B44 allelic losses in human solid tumors
Cabrera, T., Maleno, I., López‐Nevot, M. Á., Redondo, M., Fernandez, M. A., Collado, A., & Garrido, F. (2003) · Human Immunology · doi:10.1016/s0198-8859(03)00164-2 · Cited by 29 · cited 1×
“To determine the type of HLA loss occurring during tumor progression, tissue samples from breast, colorectal, and laryngeal carcinomas were analyzed [ 63 ].”
Feenstra, M., Verdaasdonk, M. A. M., Zwan, A. ‐. V. D., de Weger, R. A., Slootweg, P. J., & Tilanus, M. G. J. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780045 · Cited by 28
Griffioen, M., Ouwerkerk, I. J. M., Harten, V., & Schrier, P. I. (2000) · Immunogenetics · doi:10.1007/s002510000262 · Cited by 24 · cited 1×
“HLA allelic loss Mutations of HLA class I genes [50, 57] IV. HLA-A, HLA-B, HLA-C locus down-regulation Alteration of transcriptional factors [50, 58 , 59]”
BackgroundRees, R. C., McArdle, S., Mian, S., Li, G., Ahmad, M., Parkinson, R. J., & Ali, S. (2002) · PubMed · Cited by 23
Self-citationDisease-driven T cell activation predicts immune responses to vaccination against melanoma.
Speiser, D. E., Rimoldi, D., Batard, P., Líénard, D., Lejeune, F. J., Cerottini, J., & Romero, P. J. (2003) · PubMed · Cited by 23
Ciavarra, R. P., Brown, R. R., Holterman, D. A., Garrett, M., Glass, W. F., Wright, G. L., Schellhammer, P. F., & Somers, K. D. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0383-x · Cited by 21 · cited 1×
“demonstrated in a prostate tumor (TRAMP-C1) model where the injection of Fms-like tyrosine kinase 3 ligand (flt3-L) induced short-term tumor stabilization and regression followed by tumor relapse [10].”
BackgroundRagnarsson, G. B., Mikaelsdottir, E., Viđarsson, H., Jonasson, J. G., Ólafsdóttir, K., Kristjansdottir, K., Kjartansson, J., Ogmundsdottir, H. M., & Rafnar, Þ. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1506 · Cited by 18 · cited 2×
“breast cancer and normal tissue, as determined by immunohistochemistry, is unlikely to be an important marker for immune evasion [81].”
BackgroundMaas, R. A., Dullens, H. F. J., & Otter, W. D. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90141-s · Cited by 17
Oncogene and Cytokine Expression of Human Colorectal Tumors Responding to Immunotherapy
Doran, T., Stuhlmiller, H., Kim, J. A., Martin, E. W., & Triozzi, P. L. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199709000-00006 · Cited by 15 · cited 1×
“High concentrations of TGF-b are also found in cancer patients [101] and are usually associated with ‘‘tumor progression’’ [102] and poor responses to immunotherapy [103].”
BackgroundEscape Mechanisms in Tumor Immunity: An Update
Müller, L., Kiessling, R. W., Rees, R. C., & Pawelec, G. (2002) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v21.i4.10 · Cited by 15
Self-citationFan, X., Han, B., Dong, Q., Sha, H., Bao, G., & Liao, M. (2003) · PubMed · Cited by 12
Ahmad, M., Rees, R. C., McArdle, S., Li, G., Mian, S., Entwisle, C., Loudon, P. T., & Ali, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.20976 · Cited by 12
Self-citationTw, S., & Hui, K. M. (1991) · PubMed · Cited by 5
Cited by
Photodynamic therapy and anti-tumour immunity
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1894 · Cited by 2,676
Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., & Clay, T. M. (2008) · Blood · doi:10.1182/blood-2008-01-135319 · Cited by 300
Decreased Total Lymphocyte Counts in Pancreatic Cancer: An Index of Adverse Outcome
Fogar, P., Sperti, C., Basso, D., Sanzari, M. C., Greco, E., Davoli, C., Navaglia, F., Zambon, C.-F., Pasquali, C., Venza, E., et al. (2006) · Pancreas · doi:10.1097/01.mpa.0000188305.90290.50 · Cited by 260
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., et al. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/5/0963 · Cited by 217
The Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
Metadata
- Authors
- Ahmad, M., Rees, R., & Ali, S.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2004-06-10
- Volume
- 53
- Issue
- 10
- Pages
- 844-54
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W1984301004
- Cited by
- 183
- References
- 117
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.